Current and emerging drugs for the treatment of atherosclerosis: the evidence to date

References

• Alexander RW, Dzau VJ. Vascular biology: the past 50 years. Circulation. 2000;102(20 Suppl 4):IV112–6.
   PubMed Web of Science ®Google Scholar
• Helkin A, Stein JJ, Lin S, et al. Dyslipidemia part 1-review of lipid metabolism and vascular cell physiology. Vasc Endovascular Surg. 2016;50:107–118.
   PubMed Web of Science ®Google Scholar
• Libby P. The changing landscape of atherosclerosis. Nature. 2021;592:524–533.
   PubMed Web of Science ®Google Scholar
• Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341–355.
   PubMed Web of Science ®Google Scholar
• Kwon GP, Schroeder JL, Amar MJ, et al. Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. Circulation. 2008;117:2919–2927.
   PubMed Web of Science ®Google Scholar
• Peluso I, Morabito G, Urban L, et al. Oxidative stress in atherosclerosis development: the central role of LDL and oxidative burst. Endocr Metab Immune Disord Drug Targets. 2012;12:351–360.
   PubMedGoogle Scholar
• Rizzo M, Berneis K. Should we measure routinely the LDL peak particle size? Int J Cardiol. 2006;107:166–170.
   PubMed Web of Science ®Google Scholar
• Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204–212.
   PubMed Web of Science ®Google Scholar
• Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410–1422.
   PubMed Web of Science ®Google Scholar
• Sakakura K, Nakano M, Otsuka F, et al. Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ. 2013;22:399–411.
   PubMed Web of Science ®Google Scholar
• Bobryshev YV, Ivanova EA, Chistiakov DA, et al. Macrophages and their role in atherosclerosis: pathophysiology and transcriptome analysis. Biomed Res Int. 2016;2016:9582430.
   PubMed Web of Science ®Google Scholar
• Itabe H. Oxidized low-density lipoproteins: what is understood and what remains to be clarified. Biol Pharm Bull. 2003;26:1–9.
   PubMed Web of Science ®Google Scholar
• Bui QT, Prempeh M, Wilensky RL. Atherosclerotic plaque development. Int J Biochem Cell Biol. 2009;41:2109–2113.
   PubMed Web of Science ®Google Scholar
• Janoudi A, Shamoun FE, Kalavakunta JK, et al. Cholesterol crystal-induced arterial inflammation and destabilization of atherosclerotic plaque. Eur Heart J. 2016;37:1959–1967.
   PubMed Web of Science ®Google Scholar
• Finn AV, Nakano M, Narula J, et al. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010;30:1282–1292.
   PubMed Web of Science ®Google Scholar
• Timmis A, Townsend N, Gale CP, et al. European society of cardiology: cardiovascular disease statistics 2019. Eur Heart J. 2020;41:12–85.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–952.
   PubMed Web of Science ®Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227–3337.
   PubMedGoogle Scholar
• Toth PP, Barylski M, Nikolic D, et al. Should low high-density lipoprotein cholesterol (HDL-C) be treated? Best Pract Res Clin Endocrinol Metab. 2014;28:353–368.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Spinas GA, Cesur M, et al. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. Atherosclerosis. 2009;207:502–506.
   PubMed Web of Science ®Google Scholar
• Bayram F, Kocer D, Gundogan K, et al. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J Clin Lipidol. 2014;8:206–216.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188.
   PubMed Web of Science ®Google Scholar
• Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5:378–387.
   PubMed Web of Science ®Google Scholar
• Nikolic D, Banach M, Nikfar S, Lipid and Blood Pressure Meta-Analysis Collaboration Group, et al. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol. 2013;168:5437–5447.
   PubMed Web of Science ®Google Scholar
• Ikeda U, Shimada K. Pleiotropic effects of statins on the vascular tissue. Curr Drug Targets Cardiovasc Haematol Disord. 2001;1:51–58.
   PubMedGoogle Scholar
• Rizzo M, Berneis K. The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drugs Ther. 2006;20:205–217.
   PubMed Web of Science ®Google Scholar
• Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415–427.
   PubMedGoogle Scholar
• Bergeron N, Phan BA, Ding Y, et al. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015;132:1648–1666.
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Obradović M, et al. PCSK9 inhibition - A novel mechanism to treat lipid disorders? Curr Pharm Des. 2013;19:3869–3877.
   PubMed Web of Science ®Google Scholar
• Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088–2093.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999;159:1893–1900.
   PubMed Web of Science ®Google Scholar
• Sonne DP, Hansen M, Knop FK. Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. Eur J Endocrinol. 2014;171:R47–65.
   PubMed Web of Science ®Google Scholar
• Investigators AIM-HIG-H, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
   PubMed Web of Science ®Google Scholar
• Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease (review). J Nutr Biochem. 2003;14:298–305.
   PubMed Web of Science ®Google Scholar
• Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40–46.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.
   PubMed Web of Science ®Google Scholar
• McGowan MP, Tardif JC, Ceska R, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7:e49006.
   PubMed Web of Science ®Google Scholar
• Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126:2283–2292.
   PubMed Web of Science ®Google Scholar
• Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J. 2015;36:566–575.
   PubMed Web of Science ®Google Scholar
• Marrs JC, Anderson SL. Bempedoic acid for the treatment of dyslipidemia. Drugs Context. 2020;9:2020.
   Google Scholar
• Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380:1022–1032.
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs. placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322:1780–1788.
   PubMed Web of Science ®Google Scholar
• Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8:e011662.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27:593–603.
   PubMed Web of Science ®Google Scholar
• German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. BioDrugs. 2020;34:1–9.
   PubMed Web of Science ®Google Scholar
• Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507–1519.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382:1520–1530.
   PubMed Web of Science ®Google Scholar
• Hovingh GK, Lepor NE, Kallend D, et al. Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin/kexin type 9 expression in homozygous familial hypercholesterolemia: the ORION-2 pilot study. Circulation. 2020;141:1829–1831.
   PubMed Web of Science ®Google Scholar
• Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430–1440.
   PubMed Web of Science ®Google Scholar
• Giglio RV, Patti AM, Cicero AFG, et al. Polyphenols: potential use in the prevention and treatment of cardiovascular diseases. Curr Pharm Des. 2018;24:239–258.
   PubMed Web of Science ®Google Scholar
• Liu X, Men P, Wang Y, et al. Efficacy and safety of lomitapide in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Aug;17(4):299–309. PMID: 28255870.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020 Dec 10;383(24):2307–2319. Epub 2020 Nov 15. PMID: 33196153.
   PubMed Web of Science ®Google Scholar
• Yamashita S, Arai H, Bujo H, PROSPECTIVE Study Group, et al. Probucol trial for secondary prevention of atherosclerotic events in patients with coronary heart disease (PROSPECTIVE). J Atheroscler Thromb. 2021 Feb 1;28(2):103–123. Epub 2020 Apr 24. PMID: 32336695; PMCID: PMC7957028.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111–24.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ma X, Ilyas I, et al. Impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics. 2021;11:4502–4515.
   PubMed Web of Science ®Google Scholar
• Ma X, Liu Z, Ilyas I, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17:2050–2068.
   PubMed Web of Science ®Google Scholar
• Nikolic D, Giglio RV, Rizvi AA, et al. Liraglutide reduces carotid intima-media thickness by reducing small dense low-density lipoproteins in a real-world setting of patients with type 2 diabetes: a novel anti-atherogenic effect. Diabetes Ther. 2021;12:261–274.
   PubMed Web of Science ®Google Scholar
• Anholm C, Kumarathurai P, Pedersen LR, et al. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: a randomized trial. Atherosclerosis. 2019;288:60–66.
   PubMed Web of Science ®Google Scholar
• Berneis K, Rizzo M, Stettler C, et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. Expert Opin Pharmacother. 2008;9:343–349.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
   PubMed Web of Science ®Google Scholar
• Berndt J, Ooi SL, Pak SC. What is the mechanism driving the reduction of cardiovascular events from glucagon-like peptide-1 receptor agonists?-A mini review. Molecules. 2021 Aug 10;26(16):4822. PMID: 34443410; PMCID: PMC8400553.
   PubMed Web of Science ®Google Scholar
• Novodvorský P, Haluzík M. The effect of GLP-1 receptor agonists on postprandial lipaemia. Curr Atheroscler Rep. 2022 Jan;24(1):13–21. Epub 2022 Jan 24. PMID: 35080714.
   PubMed Web of Science ®Google Scholar
• Voukali M, Kastrinelli I, Stragalinou S, et al. Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide. J Diabetes Res. 2014;2014:304032. Epub 2014 Aug 4. PMID: 25165723; PMCID: PMC4137738.
   PubMed Web of Science ®Google Scholar
• Cariou B. Pleiotropic effects of insulin and GLP-1 receptor agonists: potential benefits of the association. Diabetes Metab. 2015 Dec;41(6 Suppl 1):6S28–6S35. PMID: 26774017.
   PubMedGoogle Scholar
• Hjerpsted JB, Flint A, Brooks A, et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018 Mar;20(3):610–619. Epub 2017 Oct 27. PMID: 28941314; PMCID: PMC5836914.
   PubMed Web of Science ®Google Scholar
• Alaaeddine RA, AlZaim I, Hammoud SH, et al. The pleiotropic effects of antithrombotic drugs in the metabolic-cardiovascular-neurodegenerative disease continuum: impact beyond reduced clotting. Clin Sci (Lond). 2021 Apr 30;135(8):1015–1051. PMID: 33881143.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Hermans MP, Fruchart-Najib J. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα): new opportunities to reduce residual cardiovascular risk in chronic kidney disease? Curr Atheroscler Rep. 2020 Jul 15;22(8):43. PMID: 32671476; PMCID: PMC7363727.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018 Dec; 206: 80–93 Epub 2018 Sep 29. PMID: 30342298
   PubMed Web of Science ®Google Scholar
• Suceveanu AI, Mazilu L, Katsiki N, et al. NLRP3 inflammasome biomarker-could be the new tool for improved cardiometabolic syndrome outcome‎. Metabolites. 2020;10(11):448.
   Web of Science ®Google Scholar
• Hoy SM. Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis. BioDrugs. 2015;29:133–142.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Anti-inflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Tocilizumab: a review in rheumatoid arthritis. Drugs. 2017;77:1865–1879.
   PubMed Web of Science ®Google Scholar
• Kleveland O, Kunszt G, Bratlie M, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016;37:2406–2413.
   PubMed Web of Science ®Google Scholar
• Broch K, Anstensrud AK, Woxholt S, et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77:1845–1855.
   PubMed Web of Science ®Google Scholar
• Ochaion A, Bar-Yehuda S, Cohn S, et al. Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression. Arthritis Res Ther. 2006;8:R169.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380:752–762.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colchicine in the treatment of gout. Clin Ther. 2014;36:1465–1479.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–2505.
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404–410.
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838–1847.
   PubMed Web of Science ®Google Scholar
• Aston NM, Bamborough P, Buckton JB, et al. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. J Med Chem. 2009;52:6257–6269.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Glaser R, Cavender MA, et al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. JAMA. 2016;315:1591–1599.
   PubMed Web of Science ®Google Scholar
• Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J Lipid Res. 2009;50 Suppl(Suppl):S376–81.
   PubMedGoogle Scholar
• Investigators STABILITY, White HD, Held C, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370:1702–1711.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014;312:1006–1015.
   PubMed Web of Science ®Google Scholar
• Bjelakovic G, Nikolova D, Gluud C. Antioxidant supplements to prevent mortality. JAMA. 2013;310:1178–1179.
   PubMed Web of Science ®Google Scholar
• Bjelakovic G, Nikolova D, Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? PLoS One. 2013;8:e74558.
   PubMed Web of Science ®Google Scholar
• Manson JE, Cook NR, Lee IM, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380:33–44.
   PubMed Web of Science ®Google Scholar
• Tardif JC, McMurray JJ, Klug E, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:1761–1768.
   PubMed Web of Science ®Google Scholar
• Al Mahmeed W, Al-Rasadi K, Banerjee Y, et al. Rizzo M and the cardiometabolic panel of international experts on syndemic covid-19 (CAPISCO). Promoting a syndemic approach for cardiometabolic disease management during COVID-19: the CAPISCO international expert panel. Front Cardiovasc Med. 2021;8:787761.
   PubMed Web of Science ®Google Scholar
• Stoian AP, Banerjee Y, Rizvi AA, et al. Diabetes and the COVID-19 pandemic: how insights from recent experience might guide future management. Metab Syndr Relat Disord. 2020;18:173–175.
   PubMed Web of Science ®Google Scholar
• Ceriello A, Stoian AP, Rizzo M. COVID-19 and diabetes management: what should be considered? Diabetes Res Clin Pract. 2020;163:108151.
   PubMed Web of Science ®Google Scholar
• Crismaru I, Pantea Stoian A, Bratu OG, et al. Low-density lipoprotein cholesterol lowering treatment: the current approach. Lipids Health Disease. 2020;19(1):85.
   PubMed Web of Science ®Google Scholar
• Abate N, Sallam HS, Rizzo M, et al. Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des. 2014;20:4961–4969.
   PubMed Web of Science ®Google Scholar
• Chyu KY, Dimayuga PC, Shah PK. Vaccine against arteriosclerosis: an update. Ther Adv Vaccines. 2017;5:39–47.
   PubMedGoogle Scholar
• Gisterå A, Hermansson A, Strodthoff D, et al. Vaccination against T-cell epitopes of native ApoB100 reduces vascular inflammation and disease in a humanized mouse model of atherosclerosis. J Intern Med. 2017;281:383–397.
   PubMed Web of Science ®Google Scholar
• Wolf D, Gerhardt T, Ley K. Vaccination to prevent cardiovascular disease. In: Zirlik A, Bode C, Gawaz M, editors. Platelets, haemostasis and inflammation. Cham Switzerland: Springer International Publishing; 2017. p. 29–52.
   Google Scholar
• Nus M, Mallat Z. Immune-mediated mechanisms of atherosclerosis and implications for the clinic. Expert Rev Clin Immunol. 2016;12:1217–1237.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–121.
   PubMed Web of Science ®Google Scholar
• Dorsheimer L, Assmus B, Rasper T, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4:25–33.
   PubMed Web of Science ®Google Scholar
• Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842–847.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018;206:80–93.
   PubMed Web of Science ®Google Scholar
• Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2021 Oct 12;ehab718. Online ahead of print. DOI:10.1093/eurheartj/ehab718.
   Google Scholar